1. Medtech Insight
  2. >>Business

Amid China Weakness Philips Stresses Value Creation And Innovation Upside

Top-Three Imaging Concern Looks To Put Respironics Issues In The Past

 
• By Ashley Yeo

Philips, the last of the global top-three imaging companies to report 2024 financial results, said the soft China market put the brakes on its growth. The regional outlook for early 2025 is no different, and US-China tariffs will present another challenge.

Greenshoots
Green shoots in China but no trigger for a trend yet • Source: Shutterstock

Once Royal Philips has battled through the practicalities of its Respironics remediation issues and factored in the uncertainties in the China market, there are positive business trends to look forward to.

That was the tenor of comments delivered to the market on 19 February by CEO Roy Jakobs, as Philips reported full-year 2024 revenues down 1% on a reported basis, at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.